Publications by authors named "S N Mohanasundaram"

The prevalence of hypertension is on the rise, with approximately 200 million individuals affected by this condition in India. Epidemiological studies suggest that one in every three adults in India has hypertension. Fixed-dose combinations (FDCs) present a potential strategy to address the challenge of effective blood pressure control.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic Limb Threatening Ischemia (CLTI) is a severe condition leading to high rates of limb amputation and cardiovascular death, particularly in cases where standard treatments fail.
  • Endovascular interventions are the main treatment strategy, but a significant number of patients are considered "no-option," prompting interest in new therapies like bone marrow-derived mesenchymal stromal cells (BM-MSC).
  • REGENACIP is an approved BM-MSC therapy in India for patients with critical limb ischemia who are not candidates for traditional revascularization, and this review discusses its potential benefits and effectiveness in treating CLTI.
View Article and Find Full Text PDF

Tuberculosis (TB) is the leading cause of infectious mortality and morbidity in the world, second only to coronavirus disease 2019. Patients with chronic kidney disease and kidney transplant recipients are at a higher risk of developing TB than the general population. Active TB is difficult to diagnose in this population due to close mimics.

View Article and Find Full Text PDF
Article Synopsis
  • - Pulmonary edema occurs when fluid builds up in the lungs' alveoli, and can be classified as either cardiogenic (related to heart issues) or noncardiogenic (not related to heart problems).
  • - Cardiogenic pulmonary edema is often linked to congestive heart failure (CHF) and is typically treated with loop diuretics, with torsemide and furosemide being effective options due to their ability to reduce heart pressure levels.
  • - Torsemide may be preferable over furosemide because it has better absorption and efficacy, showing good results when given intravenously for cardiogenic pulmonary edema, but further studies are necessary to evaluate its effectiveness in non-cardiogenic cases.
View Article and Find Full Text PDF

Hepatic edema is caused by decreased hepatic protein synthesis, a consequence of decompensated liver cirrhosis. Fluid accumulation occurs when there is an increase in hydrostatic pressure in the hepatic sinusoids and splanchnic capillaries, as well as low albumin. The first-line treatment for cirrhosis-related ascites is an aldosterone antagonist (spironolactone); however, in severe and recurring ascites, a combination of aldosterone antagonists and loop diuretics (torsemide, furosemide, and bumetanide) is preferable.

View Article and Find Full Text PDF